Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases

Abstract Approximately 30% of individuals with severe SARS-CoV-2 infections also develop neurological and psychiatric complaints. In rare cases, the occurrence of autoimmune encephalitis has been reported after SARS-CoV-2 infection. In this systematic review, we have identified eight SARS-CoV-2-asso...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Veronika Vasilevska, Paul C. Guest, Hans-Gert Bernstein, Matthias L. Schroeter, Christian Geis, Johann Steiner
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: BMC 2021-10-01
Seri Bilgileri:Journal of Neuroinflammation
Konular:
Online Erişim:https://doi.org/10.1186/s12974-021-02293-x
Diğer Bilgiler
Özet:Abstract Approximately 30% of individuals with severe SARS-CoV-2 infections also develop neurological and psychiatric complaints. In rare cases, the occurrence of autoimmune encephalitis has been reported after SARS-CoV-2 infection. In this systematic review, we have identified eight SARS-CoV-2-associated cases of anti-NMDA receptor encephalitis. All had cerebrospinal fluid antibodies against the NMDA receptor and a recent onset of working memory deficits, altered mental status, or psychiatric symptoms, such as confusion, agitation, auditory hallucination, catatonia and speech dysfunction. All patients received high-dose steroid and immunoglobulin therapeutics and conditions improved in each case. These findings suggest that clinical attention should be paid to warning signs of autoimmune encephalitis in severe COVID-19 cases. If characteristic features of autoimmune encephalitis are present, autoantibody diagnostics should be performed and confirmed cases should be treated with immunotherapy to minimize neurological impairments.
ISSN:1742-2094